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Background: Untreated post-traumatic stress disorder (PTSD) in children and adolescents is associated with a
considerable economic burden on the health system, families and society. Recent research has demonstrated the
potential efficacy of cognitive therapy as an early intervention for PTSD in children and adolescents. Children who
experienced a single traumatic event in the previous two to six months and were randomized to cognitive therapy for
PTSD (CT-PTSD) were significantly more likely to be PTSD-free compared to those randomized to usual care
represented by waitlist control. The current study evaluated the economic impact of improvements in the treatment of
PTSD in children and adolescents. Methods: A cost-effectiveness analysis was conducted from the national health
service/personal social services perspective with outcomes expressed as quality-adjusted life years (QALYs). Patient
level costs and outcomes were collected during the 11 week clinical trial and extrapolated to a three year time horizon
using economic modelling methods. Uncertainty was estimated using probabilistic sensitivity analysis and
assumptions were tested using one way sensitivity analysis. Results: The incremental cost-effectiveness ratio at
3 years was £2,205 per QALY with a 60%–69% probability of CT-PTSD being cost-effective compared to usual care at
the UK £20,000 to £30,000 per QALY decision threshold. Conclusions: This study provides preliminary evidence for
the cost-effectiveness of cognitive therapy in this treatment population. Larger pragmatic trials with longer follow-up
are indicated. Keywords: Economic evaluation; post-traumatic stress disorder; cognitive therapy.
Introduction
In peace time, more than half of children and adoles-
cents will experience, or witness, traumatic events
suchas violence, abuse, vehicle accidents, house fires,
deaths and injuries (Copeland, Keeler, Angold, &
Costello, 2007). A meta-analysis conducted in 2014
estimated that 16% of children and adolescents
exposed to traumawill go on todevelop post-traumatic
stress disorder (PTSD) (Alisic et al., 2014). Untreated,
PTSD in children and adolescents tends to have a
chroniccourseandhighcomorbiditywithothermental
health disorders such as anxiety, depression and
severe behavioural problems (Bolton, O’Ryan, Udwin,
Boyle, & Yule, 2000; Fletcher, 1996). The potential
economic burden of untreated childhood and adoles-
cent PTSD includes higher lifetime health care costs,
impaired quality of life for patients and their families,
educational difficulties and potentially poorer employ-
ment outcomes (Makley & Falcone, 2010).
There is no established best practice for early
intervention for children and adolescents at risk of
PTSD after a single traumatic event (Marsac, Donlon,
& Berkowitz, 2014), with concerns in the adult
literature that early intervention in the first four
weeks (in particular single-session psychological
debriefing) may be ineffectual or even impede natural
recovery (Rose, Bisson, Churchill, & Wessely, 2002).
The “Acute Stress Program for Children and Teen-
agers” or ASPECTs study was the first study of early
cognitive treatment for PTSD (CT-PTSD) in children
and adolescents adapted from a successful early
cognitive intervention in adults (Ehlers et al., 2003;
Meiser-Stedman et al., 2017). The intervention was
targeted towards children and adolescents diag-
nosed with PTSD, according to a developmentally
sensitive algorithm, two to six months after a single
traumatic event.
Information about the cost-effectiveness of effec-
tive interventions is an important part of changing
clinical practice and translating research into
patient benefit (Mihalopoulos et al., 2015). The
objective is to compare alternative treatment options
in terms of their relative costs and health gains,
commonly using cost-utility analysis where cost-
effectiveness is expressed as the cost per quality-
adjusted life year (QALY), a generic measure of
health gain combing survival time with a quality of
life weighting. Cost-effectiveness can be evaluated
using patient-level cost and outcome data collected
during a clinical trial (Petrou & Gray, 2011a) or
modelled using costs, outcomes and disease
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progression data from diverse sources (including
trial data; Petrou & Gray, 2011b) or assessed
through a combined approach where trial data are
extrapolated beyond the trial time horizon to capture
the longer term impact of treatment on disease
progression, costs and benefits (Hughes et al.,
2016). The current study takes the trial-based
extrapolation approach.
We systematically reviewed the cost effectiveness
literature in childhood PTSD and identified two
published economic evaluations which modelled
the cost-effectiveness of trauma-focussed cognitive
behavioural therapy (TF-CBT) for childhood and
adolescent PTSD (Gospodarevskaya & Segal, 2012;
Mihalopoulos et al., 2015). TF-CBT and CT-PTSD
are both CBT based therapies for the treatment of
child and adolescent PTSD. TF-CBT is mainly used
in chronic trauma such as sexual abuse. Gospo-
darevskaya and Segal (Gospodarevskaya & Segal,
2012) compared TF-CBT with antidepressants,
nondirective counselling and no treatment in terms
of QALYs and costs to the Australian mental health
care system, for sexually abused children and ado-
lescents with PTSD and/or depression over a 30-
year time horizon. TF-CBT dominated nondirective
counselling (achieving more QALYs at lower cost)
and was cost-effective compared to no treatment,
with costs per QALY under A$2,000, well below the
Australian cost-effectiveness threshold (the amount
a health provider is broadly prepared to pay for one
QALY) of AU$50,000. Mihalopoulos and colleagues
(Mihalopoulos et al., 2015) also modelled TF-CBT in
children but over a shorter time horizon of 5 years.
They estimated the cost per QALY at AU$8,900;
again, well under the Australian cost-effectiveness
threshold of AU$50,000.
Although both analyses concluded that TF-CBT
was cost-effective from the Australian health care
system perspective, these findings may not be gen-
eralizable to other health care systems or to the
treatment of children and adolescents at risk of
PTSD after a single acute traumatic episode. Impor-
tantly, one model concerned sexually abused young
people who are at greater risk of depression and
suicide later in life. Finally, both evaluations were
economic models that synthesized cost, outcome
and remission rates taken from different sources and
applied them to a hypothetical cohort of patients.
The present study is the first to estimate cost-
effectiveness based on patient-level cost and effect
data observed in a randomized clinical trial of CT-
PTSD for children and adolescents with recent
exposure to single-incident traumatic stressor (e.g.
motor vehicle collision, assault).
Methods
Clinical trial
The ASPECTs study was an 11-week randomized waitlist
controlled trial of early PTSD treatment in trauma exposed
children and adolescents delivered 2–6 months after a single
trauma event (Meiser-Stedman et al., 2017). The study
recruited participants from Emergency Departments, commu-
nity mental health teams, primary care, schools and other
health clinics across the East of England region. Children and
adolescents were included if they were aged 8–17 years, and
met age-appropriate diagnostic criteria for PTSD; all partici-
pants met ICD-10 criteria for PTSD. Twenty nine children were
recruited and randomized equally to CT-PTSD (n = 14) or an
11 week waitlist control group (n = 15). The treatment group
were offered individual weekly sessions of CT-PTSD over
10 weeks delivered by trained clinical psychologists. The
waitlist control group reflected usual care offered by the
English National Health Service (NHS) where early intervention
is not usually offered to treat children at risk of trauma related
PTSD. All waitlist control patients were offered CT-PTSD at
11 weeks.
Economic evaluation
The economic evaluation was a cost-utility analysis taking the
UK National Health Service/Personal Social Services perspec-
tive for costs and using QALYs as the primary economic
outcome. Resource use was collected using the Child and
Adolescent Service Use Schedule (CA-SUS), designed and
successfully implemented in various evaluations of child and
adolescent mental health services (Goodyer et al., 2017), and
clinical records for intervention contact time. Resource use
associated with the index trauma such as accident and
emergency department attendance was excluded. All services
used were costed using nationally applicable unit costs at
2014 prices (Curtis, 2014). The intervention cost was based on
the contact time multiplied by the hourly unit cost for a clinical
psychologist (UK NHS Agenda for Change Band 8a) of £138 per
hour including employer costs (national insurance and super-
annuation), overhead costs and noncontact time (Curtis,
2014). The 14 young people in the treatment group received
an average of 636.25 min of contact time (range 195–755 min)
and attended an average of 8.3 sessions (range 4–10) at a mean
cost of £1463.
Utility weights used to calculate QALYs were derived from
the parent-completed Strengths and Difficulties Questionnaire
(SDQ), a commonly used measure of mental health in children
and adolescents (Goodman, 2007). SDQ scores were mapped
to the Child Health Utility index 9D (CHU-9D) using a
published mapping algorithm developed in a sample of 200
caregivers of young people in Australia attending child and
adolescent mental health services (Furber, Segal, Leach, &
Cocks, 2014). The CHU-9D is a generic measure of children’s
health state preferences consisting of nine dimensions (sad,
worried, pain, annoyed, tired, homework or schoolwork, daily
routine, activities and sleep) rated using five levels (Stevens,
2012). The CHU-9D is recognized as a valid and responsive
utility measure designed exclusively for use in children (Can-
away & Frew, 2013). The algorithm mapping the SDQ to the
CHU-9D performed well in predicting mean group observed
utility values. Equation 1 transforms the five SDQ subscale
scores into a utility value or weight which is used to calculate
QALYs.
Utility ¼ 0:88þ ð0:019 emotionÞ
þ ð0:009 conductÞ þ ð0:001 hyperÞ
þ ð0:008 peerÞ þ ð0:005 prosocialÞ
ð1Þ
A QALY is calculated by multiplying survival time by a utility
weight. For example, if a child lives two years with quality-of-
life weighted at 0.5, the two life years are multiplied by 0.5 to
yield one QALY.
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Economic model
An economic model was developed to extrapolate costs and
consequences expected to occur after the initial trial period.
This was a Markov model with two health states defined by
PTSD diagnosis (PTSD or PTSD-free). The children entered the
model according to their group allocation and PTSD status at
the end of the 11 week trial (see Figure 1). A time horizon of
three years was selected since most natural recovery occurs
within three years of an acute traumatic event (Breslau, 2009).
The children move through the Markov model in three-month
cycles accruing costs and QALYs depending on whether they
are in the PTSD health state or the PTSD-free health state
(Figure 2). The three month cycle length was an approximation
of the 11 week trial period. The PTSD health state value was
based on the mean costs and QALYs of children at baseline
(n = 29). The PTSD-free health state value was based on the
costs (excluding the cost of CT-PTSD) and QALYs for all
children who were PTSD-free at trial follow up irrespective of
group allocation (n = 14). Natural recovery was simulated
using transition probabilities estimated from a meta-analytic
study of child post-traumatic stress disorder (Hiller et al.,
2016). These reflect the probability that a PTSD patient will
recover at the end of each three month time cycle in the first
year. Hiller et al. (2016) found prevalence of PTSD reduced by
34% between 3 and 12 months after diagnosis. The nine
month probability of .34 from (Hiller et al., 2016) was con-
verted to an instantaneous nine-month rate, divided by three
to derive the three-month rate, and then the three-month rate
was converted to a three-month probability of .129 as recom-
mended by (Miller & Homan, 1994). Natural recovery was not
modelled in years 2 and 3 as there was little evidence of further
significant spontaneous recovery after one year (Gospo-
darevskaya & Segal, 2012; Hiller et al., 2016). Once recovered
from a single acute traumatic event, the risk of relapse is
considered very low (Hong et al., 2014) and is not considered in
the model. Costs and QALYs after the first year were dis-
counted at the UK Treasury rate of 3.5% to reflect time
preferences (Shearer & Byford, 2015). The model summed total
costs and QALYs for each group over 2 years and 9 months
which, added to the trial based costs and QALY data, provided
the data for the cost-utility analysis.
We recommend that readers unfamiliar with health eco-
nomic methods refer to the following helpful primer papers
designed for clinicians on economic evaluation (Shearer &
Byford, 2015) and economic modelling (Petrou & Gray, 2011b).
Analysis
The cost effectiveness of CT-PTSD relative to usual care is
presented as an incremental cost- effectiveness ratio (ICER)
which is the difference in mean costs divided by the difference
in mean QALYs, expressed as the cost per QALY. CT-PTSD is
considered cost effective from the perspective of the UK
National Institute for Health and Care Excellence (NICE) if
the ICER is below £20,000 to £30,000 per QALY (McCabe,
Claxton, & Culyer, 2008). Probabilistic sensitivity analysis
(PSA) was used to estimate parameter uncertainty in the
model. This involves multiple, simultaneous draws from prob-
ability distributions around uncertain model parameters
including transition probabilities, health state values, efficacy
and natural recovery (Van Hout, Al, Gilad, Gordon, & Rutten,
1994). The parameter values and distributions and data
sources used in the PSA appear in Table 1. Cost-effectiveness
acceptability curves (CEAC) are derived from the joint distri-
bution of the difference in costs and differences in effects
generated by the PSA. The CEAC shows the probability that
CT-PTSD is cost-effective compared to usual care at the NICE
threshold and also for a range of alternative willingness to pay
thresholds (Fenwick & Byford, 2005). One-way sensitivity
analyses were performed testing the inclusion of training costs
and a complete case analysis. Trial-based costs and QALYs
were adjusted for baseline differences in costs or utility
weights, respectively, and potential clinical predictors (age,
gender, group) using generalized linear modelling. Missing cost
and outcome data were imputed using conditional regression.
Analyses were conducted in STATA 14C and Excel.
Results
Trial costs
Resource use during the trial and mean costs per
child by group are summarized in Table 2. A detailed
breakdown of costs at follow up could only be
calculated for those children who completed follow-
up interviews. Thus, in Table 2 the mean cost of CT-
PTSD of £1441 was for the 12 children who were
followed up which was slightly lower than the mean
cost of the CT-PTSD intervention for all 14 children
in the CT-PTSD group which was £1463.
Trial outcomes
Trial outcomes are presented in Table 3. Cost and
QALY data were missing due to noncompletion of
questionnaires and losses to follow-up. Missing cost
and QALY data were not significantly different
between groups (p = .366). Accordingly, we imputed
missing cost and QALY data using conditional
regression.
N = 4
N = 11
PTSD
N = 10
PTSD-free
N = 4
PTSD
CT-PTSD
Waitlist
PTSD-free
Markov Model
2 years 9 months
3 month cycles
Clinical trial 
11 weeks
Figure 1 Decision model
PTSD Recovery PTSD-
free
Figure 2 Patient flow for Markov model
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Trial based cost-utility analysis
Point estimates for ICERs for complete cases and
imputed trial data are presented in Table 4. ICERs in
both cases are substantially higher than the recom-
mended threshold of between £20,000 and £30,000
per QALY but interpretation of the ICERs is limited
by the short trial time horizon and lack of longer term
follow up due to the waitlist control design.
Model based cost-utility analysis
Parameter values. Values for model health states,
derived from imputed trial data and baseline data,
are presented in Table 5. The initial distribution was
71% PTSD free for treated patients and 27% for
untreated patients.
Point estimates for ICERs based on deterministic,
patient-level costs and QALYs at four time points are
presented in Table 6. The 3-year ICER was £2,250
per QALY which is well below the NICE threshold of
between £20,000 and £30,000 per QALY suggesting
that CT-PTSD was cost-effective from the UK NHS
perspective compared to usual care. Figure 3 shows
Table 1 Parameter values, sources and uncertainty distributions for the PSA
Parameter Values (95% CI) Distribution Source
CT-PTSD efficacy 71% (58%–92%) Beta(a 19 b 7) Trial data
Usual care efficacy 27% (8%–55%) Beta (a 3 b 9) Trial data
Remission (between
3 months and year 1)
34% (21%–49%) Beta (a 14 b 95) Hiller et al. (2016)
Remission (years 2 & 3) 0% – Hiller et al. (2016)
PTSD health state costs £549 (£377–£721) Gamma(a 19.532 ϒ 28.118) Trial data
PTSD free costs £236 (£93–£379) Gamma (a 10.369 ϒ 22.738) Trial data
PTSD heath state QALY 0.185 (0.158–0.212) Beta (a 2618 b 10940) Trial data
PTSD free QALYs 0.193 (0.186–0.199) Beta (a 808 b 3567) Trial data
PSA, Probabilistic sensitivity analysis; PTSD, post-traumatic stress disorder; QALYs, quality-adjusted life years.
Table 2 Disaggregated, unadjusted mean (standard deviation) costs by group and time (complete cases) for the trial period
Baseline Follow-up
CT-PTSD (n = 14)
Mean £ (SD)
Usual care (n = 15)
Mean £ (SD)
CT-PTSD (n = 12)
Mean £ (SD)
Usual care (n = 11)
Mean £ (SD)
CT-PTSD 0 (0) 0 (0) 1441 (809) 0 (0)
Inpatient 0 (0) 0 (0) 0 (0) 0 (0)
Outpatient 68 (176) 82 (172) 48 (104) 86 (238)
Emergency Department 37 (71) 17 (35) 0 (0) 0 (0)
Ambulance 100 (191) 47 (93) 0 (0) 42 (139)
Total hospital services 205 (355) 146 (188) 48 (104) 128 (260)
GP home visit 78 (128) 98 (247) 30 (101) 0 (0)
GP surgery 110 (182) 89 (114) 45 (50) 104 (119)
GP Phone 0 (0) 0 (0) 9 (24) 10 (32)
GP Nurse 1 (2) 4 (10) 1 (3) 0 (0)
District nurse 17 (51) 4 (16) 36 (100) 13 (28)
Paediatrician 0 (0) 3 (12) 0 (0) 4 (14)
Clinical psychologist 0 (0) 23 (54) 6 (19) 0 (0)
CAMHS worker 0 (0) 31 (66) 0 (0) 42 (132)
Counsellor 43 (86) 44 (108) 17 (31) 19 (57)
Educational psychologist 30 (107) 27 (100) 0 (0) 0 (0)
Advice service 2 (6) 44 (148) 0 (0) 9 (22)
Social services 0 (0) 0 (0) 25 (16) 19 (58)
Other services 32 (110) 72 (468) 14 (45) 0 (0)
Medications 19 (71) 0 (0) 19 (63) 4 (11)
Total community services 332 (83) 432 (119) 202 (47) 223 (59)
Total costs 537 (102) 578 (119) 1691 (532) 351 (392)
GP, general practitioner; CAMHS, child and adolescent mental health service; PTSD, post-traumatic stress disorder.
Table 3 Complete case and imputed trial outcomes by group
Outcome CT-PTSD Usual care
Unadjusted
difference
Complete case n = 10 n = 11
PTSD
cases; n (%)
1 (10%) 9 (82%) 72%
QALYs;
mean (SD)
0.1933
(0.0119)
0.1846 (0.0196) .0087
Imputed data n = 14 n = 15
PTSD cases;
n (%)
4 (29%) 11 (73%) 44%
QALYs;
mean (SD)
0.1979
(0.0137)
0.1823 (0.0188) .0156
PTSD, post-traumatic stress disorder; QALYs, quality-adjusted
life years.
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5,000 scatterplots generated by the PSA. Most scat-
terplots (69%) were in the north-eastern quadrant
where the costs and QALYs for CT-PTSD were higher
than usual care. Figure 4 is a cost-effectiveness
acceptability curve derived from the scatterplot
which shows that CT-PTSD has a probability of
being cost-effective compared to usual care of 60%–
69% at the NICE £20,000 to £30,000 per QALY
threshold.
Sensitivity analysis
Complete case analysis. The model based on
complete case data differed from the imputed model
in terms of the sample size (CT-PTSD = 10, usual
care = 11), the initial distribution of recovered
patients (CT-PTSD 90%, usual care 18%) and values
for costs and QALYs in the PTSD free health state
(£264.55, 0.2027 QALYs). The 3-year ICER was
£2,806 per QALY which was comparable to the
imputed model. PSA showed that CT-PTSD had a
probability of being cost-effective compared to usual
care of between 69% and 75% at the NICE £20,000 to
£30,000 per QALY threshold using only complete
case data.
Training of therapists. Training costs were
excluded from the primary analysis because it was
assumed that CT-PTSD specific training would be
part of usual professional development. In addition,
training and specialist supervision time was only
collected for those delivering CT-PTSD; these data
were not recorded for the waitlist control group. It
may well be, however, that the intervention will
require additional training and supervision com-
pared to standard professional development. To
reflect benefits for future patients, training costs
were amortized over 5 years assuming an annual
patient caseload equivalent to the trial recruitment of
29 per annum. This produced an additional cost of
£186 per treated patient during the treatment phase.
The addition of training costs increased the three
year ICER to £16,187 per QALY and reduced the
probability of cost-effectiveness compared to usual
care to between 51% and 62% at the NICE £20,000 to
£30,000 per QALY threshold.
Discussion
This model-based cost utility analysis, using cost
and QALY data collected from a randomized clinical
trial extrapolated over the longer term, provides
preliminary support that CT-PTSD may be cost-
effective from the UK NHS perspective over a three
year time horizon. This result was driven by large
differences in the proportion of patients who recov-
ered after receiving CT-PTSD (71%) compared to
natural remission in the usual care group (27%).
Even after factoring continuing natural remission in
the first year, the upfront cost of providing CT-PTSD
was gradually offset by savings as the proportionally
greater number of recovered youths in the treatment
group imposed fewer health and social care costs
and had better quality of life compared to those with
persistent PTSD who were predominantly in the
Table 4 Trial based cost utility analysis
Costs CT-PTSD
Mean £ (SD)
Usual care
Mean £ (SD)
Adjusted
difference
QALYs
CT-PTSD
Mean (SD)
Usual care
Mean (SD)
Adjusted
difference
ICER
£ per QALY
Complete case £1,691 (£532) £351 (£392) £1,284 0.1929 (0.0108) 0.1851 (0.0201) .0103 £124,660
Imputed £1,686 (£549) £307 (£352) £1,346 0.1979 (0.0137) 0.1823 (0.0186) .0095 £141,684
ICER, incremental cost- effectiveness ratio; PTSD, post-traumatic stress disorder; QALYs, quality-adjusted life years.
Table 5 Estimated annual health state values
Health state Costs QALYs
PTSD free £1,114 .7725
PTSD £2,596 .7386
PTSD, post-traumatic stress disorder; QALYs, quality-adjusted
life years.
Table 6 Model based cost-utility analysis
Costs QALYs
ICER (£ per QALY) CEAC (p)aCT-PTSD Usual care Difference CT-PTSD Usual care Difference
Trial £1,686 £307 £1,346 0.198 0.182 .0095 £141,684
Year 1b £2,598 £1,540 £1,058 0.773 0.748 .0246 £42,967 4%–19%
Year 2 £3,752 £3,125 £627 1.557 1.522 .0352 £17,779 31%–45%
Year 3 £4,865 £4,768 £97 2.370 2.324 .0577 £2,205 60%–69%
aProbability that CT-PTSD is cost-effective at the NICE threshold of £20,000 to 30,000 per QALY.
bYear 1 data consist of 3-month trial data and 9-month modelled data.
ICER, incremental cost- effectiveness ratio; PTSD, post-traumatic stress disorder; QALYs, quality-adjusted life years.
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waitlist control condition. The three-year ICER for
CT-PTSD compared to usual care control was £2,205
per QALY, which is well below the NICE threshold of
£20,000 to £30,000 per QALY. CT-PTSD was likely to
be more cost-effective compared to usual care based
on probabilistic simulation methods.
In long-term conditions such as PTSD, the main
savings and benefits from effective treatments occur
well beyond the time horizon of the trial. As a result,
trial based cost-effectiveness analyses may under-
estimate the true cost-effectiveness of new treat-
ments. In this study we extrapolated the trial data
using decision analytic methods to model future
costs and benefits over a three year period based on
the natural history of remission. Other models have
modelled economic outcomes over longer periods (5
and 30 years), however, using our trial data, cost-
effectiveness became apparent by the third year
primarily due to the large initial between-group
differences in remission and consequent reductions
in healthcare costs associated with untreated PTSD;
extrapolation over a longer period would have con-
tinued to show improved cost-effectiveness over
time.
In this study, children’s health-related quality of
life was not directly measured by the CHU-9D utility
measure or any other direct measure of utility. The
CHU-9D utility values were calculated using a sta-
tistical mapping function estimated in an Australian
study of 200 caregivers who had completed both the
SDQ and the CHU-9D. There are limitations to this
approach, including the generalizability of a map-
ping function based on a sample of Australian
parents with children receiving community mental
health services to our sample of UK parents with
children diagnosed with PTSD. Furthermore, the
parent-report SDQ has been found to only have a
weak correlation with the symptoms of child-report
PTSD (McDermott, Lee, Judd, & Gibbon, 2005)
which may underestimate the true impact of symp-
toms on quality of life and underestimate the cost-
effectiveness of CT-PTSD. However, this was the only
method available to derive the utility values needed
to support this evaluation. We recommend that
investigators in future studies include instruments
that can directly provide utility values, such as the
CHU-9D.
There was uncertainty in the model, particularly
around the way that costs and utilities were attrib-
uted to the PTSD and PTSD-free health states. In the
absence of any UK or comparable international data,
we used the baseline results to estimate costs and
utilities for children and young people with PTSD
persisting 2–6 months after a traumatic event. The
utility value of 0.734 was higher than those used in
two Australian models which used the literature to
estimate lower utility values for adult PTSD-cases
(0.57 (Mihalopoulos et al., 2015)) and for untreated
sexually abused girls with PTSD (0.61 (Gospo-
darevskaya & Segal, 2012)) although the Australian
–£4,000
–£3,000
–£2,000
–£1,000
£0
£1,000
£2,000
£3,000
–0.1 –0.05 0 0.05 0.1 0.15 0.2
In
cr
em
en
ta
l c
os
ts
Incremental QALYs
Figure 3 Scatterplot showing the mean differences in total costs and QALYs of CT-PTSD and usual care at 3 years (modelled data)
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Figure 4 Cost-effectiveness acceptability curve showing the prob-
ability (Y-axis) that CT-PTSD is cost-effective compared to usual
care for different values (X-axis) a decision maker is willing to pay
for an extra QALY
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estimates included chronic trauma from domestic
violence and sexual abuse.
These results come with several important caveats.
Most obvious is the small sample size (n = 29) and
limited follow-up (11 weeks). Recruiting appropriate
patients within the narrow treatment window makes
research in this population difficult and sample sizes
are necessarily small. Economic modelling makes
the most of these inherently scarce data. Despite the
sample size and follow-up limitations, the treatment
effect was significant and treated patients gained
more QALYs than untreated ones. The intervention
was delivered by clinical researchers and results
may be difficult to replicate in general practice.
However, when training costs were included in a
sensitivity analysis, this did not substantially
change the probability (51%–62%) that CT-PTSD
was likely to be cost-effective compared to usual care
from the NHS/personal social services perspective.
Nevertheless, a larger pragmatic trial is needed with
longer follow-up, and in more heterogeneous popu-
lations such as urban areas, to confirm effective-
ness, generalizability and cost-effectiveness.
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Key Points
• Untreated PTSD in children and adolescents is a burden on health systems and families.
• Early intervention with Cognitive Therapy has been found to be efficacious in helping children and
adolescents to recover from PTSD.
• The long-term cost-effectiveness of interventions for PTSD in children and adolescents is important from the
policy and practice perspectives.
• CT-PTSD is potentially a cost-effective use of scarce NHS resources.
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